Umbrella review of meta-analyses: perioperative immune checkpoint inhibitor therapy in resectable gastric and gastroesophageal junction adenocarcinoma
Abstract
BackgroundImmune checkpoint inhibitors (ICIs) have entered the perioperative treatment of resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, and perioperative durvalumab plus FLOT is now the standard of care. Numerous meta-analyses on this question have appeared. This umbrella review appraises their methodological quality, quantifies their overlap, grades the credibility of each pooled outcome and re-analyses the randomized evidence at the trial level.MethodsPubMed/MEDLINE, Embase, Web of Science, Scopus and the Cochrane Library were searched from January 1, 2020 to July 31, 2026 for systematic reviews with meta-analysis of perioperative (neoadjuvant and/or adjuvant) ICI therapy in resectable G/GEJ adenocarcinoma.ResultsNineteen meta-analyses met the eligibility criteria (six comparative RCT-only, seven comparative mixed-design, six single-arm syntheses). The comparative reviews re-analyze nine randomized trials comprising 2,974 unique randomized participants (2,718 in the six pivotal datasets); overlap was very high (CCA 44.4% across all randomized comparisons, 100% for EFS and OS). pCR was consistently increased (Rodrigues et al. RR 2.93, 95% CI 2.39–3.59; umbrella re-analysis of six randomized datasets, n=2,718: 17.7% vs 6.2%, Ioannidis Class II). Event-free survival improved (HR 0.76, 95% CI 0.66–0.86; Class III). OS improved in the RCT-only synthesis that incorporates the final MATTERHORN analysis (HR 0.82, 95% CI 0.71–0.94, P = .005; Class IV by the strict P-value threshold) and in MATTERHORN itself (HR 0.78, 95% CI 0.63–0.96, P = .021). Grade ≥3 treatment-related adverse events were not increased (RR 1.07, 95% CI 0.97–1.17), immune-related adverse events were (RR 3.18, 95% CI 2.48–4.08; Class II), and surgical morbidity, R0 resection and 30-day mortality were unchanged. MSI-H/dMMR status predicted the largest pCR gain (RR 5.18, 95% CI 2.43– 11.05); PD-L1 was an assay-dependent modifier and MATTERHORN’s benefit was independent of PD-L1.ConclusionsPerioperative chemo-immunotherapy is a new standard of care for resectable G/GEJ adenocarcinoma with demonstrated pCR, EFS and OS benefit. The many meta-analyses are not independent corroboration but repeated re-analyses of a small shared set of trials, and their credibility is bounded by the primary trials, not by their number. Immune-related toxicity, not surgical morbidity, is the principal cost; MSI/MMR and assay-specified PD-L1 testing should inform, but not gate, patient selection.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261474260, identifier CRD420261474260.
Related
- Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials
- Neoadjuvant immunotherapy for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
- Efficacy and safety of apatinib-containing neoadjuvant regimens for resectable gastric and gastroesophageal junction adenocarcinoma: a systematic review and single-arm meta-analysis
- Case Report: Four-year durable remission, cerebral oligoprogression, and femoral head necrosis following severe recurrent immune checkpoint inhibitor-related pneumonitis in a patient with stage IV lung adenocarcinoma
- Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
BibTeX
@article{ghidini2026umbrella,
title = {{Umbrella review of meta-analyses: perioperative immune checkpoint inhibitor therapy in resectable gastric and gastroesophageal junction adenocarcinoma}},
author = {Michele Ghidini and Gloria Arena and Lorenzo Dottorini and Valentina Rampulla and Annamaria De Giorgi and Gianluca Tomasello and Fausto Petrelli},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1911150},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1911150},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Umbrella review of meta-analyses: perioperative immune checkpoint inhibitor therapy in resectable gastric and gastroesophageal junction adenocarcinoma
AU - Michele Ghidini
AU - Gloria Arena
AU - Lorenzo Dottorini
AU - Valentina Rampulla
AU - Annamaria De Giorgi
AU - Gianluca Tomasello
AU - Fausto Petrelli
PY - 2026
DA - 2026/11/05
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1911150
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1911150
AB - BackgroundImmune checkpoint inhibitors (ICIs) have entered the perioperative treatment of resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, and perioperative durvalumab plus FLOT is now the standard of care. Numerous meta-analyses on this question have appeared. This umbrella review appraises their methodological quality, quantifies their overlap, grades the credibility of each pooled outcome and re-analyses the randomized evidence at the trial level.MethodsPubMed/MEDLINE, Embase, Web of Science, Scopus and the Cochrane Library were searched from January 1, 2020 to July 31, 2026 for systematic reviews with meta-analysis of perioperative (neoadjuvant and/or adjuvant) ICI therapy in resectable G/GEJ adenocarcinoma.ResultsNineteen meta-analyses met the eligibility criteria (six comparative RCT-only, seven comparative mixed-design, six single-arm syntheses). The comparative reviews re-analyze nine randomized trials comprising 2,974 unique randomized participants (2,718 in the six pivotal datasets); overlap was very high (CCA 44.4% across all randomized comparisons, 100% for EFS and OS). pCR was consistently increased (Rodrigues et al. RR 2.93, 95% CI 2.39–3.59; umbrella re-analysis of six randomized datasets, n=2,718: 17.7% vs 6.2%, Ioannidis Class II). Event-free survival improved (HR 0.76, 95% CI 0.66–0.86; Class III). OS improved in the RCT-only synthesis that incorporates the final MATTERHORN analysis (HR 0.82, 95% CI 0.71–0.94, P = .005; Class IV by the strict P-value threshold) and in MATTERHORN itself (HR 0.78, 95% CI 0.63–0.96, P = .021). Grade ≥3 treatment-related adverse events were not increased (RR 1.07, 95% CI 0.97–1.17), immune-related adverse events were (RR 3.18, 95% CI 2.48–4.08; Class II), and surgical morbidity, R0 resection and 30-day mortality were unchanged. MSI-H/dMMR status predicted the largest pCR gain (RR 5.18, 95% CI 2.43– 11.05); PD-L1 was an assay-dependent modifier and MATTERHORN’s benefit was independent of PD-L1.ConclusionsPerioperative chemo-immunotherapy is a new standard of care for resectable G/GEJ adenocarcinoma with demonstrated pCR, EFS and OS benefit. The many meta-analyses are not independent corroboration but repeated re-analyses of a small shared set of trials, and their credibility is bounded by the primary trials, not by their number. Immune-related toxicity, not surgical morbidity, is the principal cost; MSI/MMR and assay-specified PD-L1 testing should inform, but not gate, patient selection.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261474260, identifier CRD420261474260.
SN - 2234-943X
ER -